Could Colchicine Be the New Aspirin? Could Colchicine Be the New Aspirin?

Michel Zeitouni talks to Jean-Claude Tardif about the COLCOT series of clinical trials testing colchicine, an anti-inflammatory gout drug, for the prevention and treatment of cardiovascular disease.theheart.org on Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Expert Interview Source Type: news

Related Links:

As you probably know, the FDA recently approved a monoclonal antibody called aducanumab as a treatment for Alzheimer's disease. To make a long story short, there's no good evidence that it actually has any effect on dementia; the approval is based on its effectiveness in removing abnormal plaques of a protein called beta-amyloid from the brain. These are associated with Alzheimer's disease, but there's no evidence that they cause it, or that removing them improves symptoms. Aducanumab can also have some very troubling adverse effects such as brain swelling. Oh yeah -- Biogen plans to charge $56,000/year for the treatment.&...
Source: Stayin' Alive - Category: American Health Source Type: blogs
Gout is the most frequent form of inflammatory arthritis in the world. Its prevalence is particularly elevated in specific geographical areas such as in the Oceania/Pacific region and is rising in the US, Europe, and Asia. Gout is a severe and painful disease, in which co-morbidities are responsible for a significant reduction in life expectancy. However, gout patients remain ostracized because the disease is still considered “self-inflicted”, as a result of unhealthy lifestyle and excessive food and alcohol intake. While the etiology of gout flares is clearly associated with the presence of monosodium urate (M...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In conclusion, we successfully demonstrated that the ε2 haplotype, but not the ε4 haplotype, incre ases SUA levels. These findings will improve our understanding of genetic factors affecting SUA levels.
Source: Human Cell - Category: Cytology Source Type: research
Conclusion: This is the first study on changes in brain cortical thickness and SCN based on graph theory in patients with gout. The present study found that, compared with healthy controls, gout patients show regional cortical thinning or thickening, and variation in the properties of the cortical thickness covariance network also changed. These alterations may be the combined effect of disease damage and physiological compensation. More research is needed to fully understand the complex underlying mechanisms of gout brain variation.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
ObjectiveTo clarify the relationship between serum urate (SU) decrease and visceral fat area (VFA) reduction in patients with gout.MethodsWe retrospectively analyzed 237 male gout patients who had two sets of body composition and metabolic measurements within 6 months. Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). All patients were from the specialty gout clinic of The Affiliated Hospital of Qingdao University. The multiple linear regression model evaluated the relationship between change in SU [...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
THE UNPRECEDENTED scale of the vaccine rollout has proven an effective shield against infection. For those who do become infected and become seriously ill, however, current go-to treatments are massively limited. One new study has suggested the gout drug remdesivir could be a prime candidate to treat severely ill COVID-19 patients.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Nefrologia. 2021 Sep 6:S0211-6995(21)00142-9. doi: 10.1016/j.nefro.2021.03.013. Online ahead of print.ABSTRACTGout is recurrent inflammatory arthritis caused by the deposition of monosodium urate crystals in the joints. The risk factors that predispose to suffering from gout include non-modifiable factors such as gender, age, ethnicity and genetics, and modifiable factors such as diet and lifestyle. It has been shown that the heritability of uric acid levels in the blood is greater than 30%, which indicates that genetics play a key role in these levels. Hyperuricaemia is often a consequence of reduced renal urate excretion...
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - Category: Urology & Nephrology Authors: Source Type: research
Int J Biol Macromol. 2021 Sep 7:S0141-8130(21)01908-5. doi: 10.1016/j.ijbiomac.2021.08.231. Online ahead of print.ABSTRACTXanthine oxidase (XO) plays a vital role in inducing hyperuricemia and increasing the level of superoxide free radicals in blood, and is proved as an important target for gout. Chrysoeriol (CHE) is a natural flavone with potent XO inhibitory activity (IC50 = 2.487 ± 0.213 μM), however, the mechanism of interaction is still unclear. Therefore, a comprehensive analysis of the interaction between CHE and XO was accomplished by enzyme kinetics, isothermal titration calorimetry (ITC), multi-spectro...
Source: International Journal of Biological Macromolecules - Category: Biochemistry Authors: Source Type: research
Nefrologia. 2021 Sep 6:S0211-6995(21)00142-9. doi: 10.1016/j.nefro.2021.03.013. Online ahead of print.ABSTRACTGout is recurrent inflammatory arthritis caused by the deposition of monosodium urate crystals in the joints. The risk factors that predispose to suffering from gout include non-modifiable factors such as gender, age, ethnicity and genetics, and modifiable factors such as diet and lifestyle. It has been shown that the heritability of uric acid levels in the blood is greater than 30%, which indicates that genetics play a key role in these levels. Hyperuricaemia is often a consequence of reduced renal urate excretion...
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - Category: Urology & Nephrology Authors: Source Type: research
Bioorg Chem. 2021 Sep 2;116:105321. doi: 10.1016/j.bioorg.2021.105321. Online ahead of print.ABSTRACTHyperuricemia is a principal factor mediating gout and kidney damage, and xanthine oxidase (XOD) is a key enzyme in the pathogenesis of hyperuricemia. In this context, a series of geniposide derivatives were designed and synthesized, and antihyperuricemic and nephroprotective effects of all derivatives was evaluated in vitro and in vivo. Compound 2e emerged as the most potent XOD inhibitor, with an IC50 value of 6.67 ± 0.46 µM. Simultaneously, cell viability, ROS generation, and SOD levels assay showed that com...
Source: Bioorganic Chemistry - Category: Chemistry Authors: Source Type: research
More News: Aspirin | Cardiology | Cardiovascular | Clinical Trials | Colchicine | Colcrys | Gout | Health | Heart